Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €3.64 EUR
Change Today -0.195 / -5.09%
Volume 1.0M
ZEL On Other Exchanges
As of 11:38 AM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

zeltia sa (ZEL) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/27/15 - €4.33
52 Week Low
10/16/14 - €2.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZELTIA SA (ZEL)

Related News

No related news articles were found.

zeltia sa (ZEL) Related Businessweek News

No Related Businessweek News Found

zeltia sa (ZEL) Details

Zeltia, S.A. operates in the chemical and biopharmaceutical sectors in Spain and internationally. The company operates through Biopharmaceuticals and Consumer Chemicals segments. The Biopharmaceuticals segment researches, develops, and markets antitumor drugs; develops and markets diagnosis kits; and develops therapies based on reducing or silencing gene expression. This segments products include Yondeli, a marketed product for the treatment of ovarian cancer and soft tissue sarcoma; Aplidi, which is in Phase III trials for the treatment of multiple myeloma, as well as for T cell lymphoma; PM1183, which has completed Phase IIb trials for the treatment of ovarian cancer; and PM184 that is in Phase I trials for the treatment of solid tumors, as well as ISYL040012, which is in Phase IIB clinical trials for the treatment of glaucoma. The Consumer Chemicals segment produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and related products. Further, the company provides services for treating and protecting wood, and repairing and preserving structures, as well as insect control and disinfection services. Zeltia, S.A. was founded in 1939 and is based in Madrid, Spain.

Founded in 1939

zeltia sa (ZEL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zeltia sa (ZEL) Key Developments

Zeltia Reports Earnings Results for the First Quarter of 2015

Zeltia reported earnings results for the first quarter of 2015. For the period, the company's net profit dropped 61% to EUR 6.5 million (USD 7.1 million) compared with EUR 16.9 million in the equivalent period of 2014. Net sales in the biopharmaceutical sector amounted to EUR 21.1 million, compared with EUR 20.9 million in first-quarter 2014. The main reason for Zeltia's negative financial performance during the beginning of the year is the reduction in milestone payment under an agreement signed with Janssen in 2011 on the development of oncology product Yondelis, which for first-quarter 2015 corresponded to only USD 10 million, compared with USD 25 million in first-quarter 2014.

Zeltia SA Presents at UBS Global Healthcare Conference, May-18-2015

Zeltia SA Presents at UBS Global Healthcare Conference, May-18-2015 . Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: José-Luis Moreno, IR & Capital Markets Director.

Zeltia SA Reports Earnings Results for the Full Year 2014

Zeltia SA reported earnings results for the full year 2014. For the year, the company reported group total revenues amounted to EUR 178 million up 8% with respect to EUR 164.7 million in 2013. Group EBITDA amounted to EUR 25.7 million, up 8% year-on-year. This improvement in operating profit was achieved despite the increase in R&D spending, which amounted to EUR 52.5 million in 2014, up 23% year-on-year. Of that figure, EUR 45.3 million corresponds to the oncology area. net attributable profit amounted to EUR 13.1 million, compared with EUR 11.3 million in 2013 (+16%).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEL:SM €3.64 EUR -0.195

ZEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEL.
View Industry Companies

Industry Analysis


Industry Average

Valuation ZEL Industry Range
Price/Earnings 100.0x
Price/Sales 5.8x
Price/Book 12.5x
Price/Cash Flow 321.1x
TEV/Sales 5.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZELTIA SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at